• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病是肺移植后死亡的一个主要危险因素。

Diabetes is a major risk factor for mortality after lung transplantation.

机构信息

Department of Medicine, Monash University, Melbourne, Australia; Department of Endocrinology and Diabetes, The Alfred Hospital, Melbourne, Australia.

出版信息

Am J Transplant. 2014 Feb;14(2):438-45. doi: 10.1111/ajt.12561. Epub 2014 Jan 8.

DOI:10.1111/ajt.12561
PMID:24401019
Abstract

Survival following lung transplant (LTx) remains significantly lower than after other solid organ transplants. Diabetes mellitus (DM) is a mortality risk factor not comprehensively studied in LTx recipients. Notably, neither the relation of time of DM onset to survival nor the actual causes of DM-associated excess mortality have been described. We determined DM status, DM diagnosis date and all-cause mortality in 386 consecutive adults who underwent LTx at our institution from January 1, 2001 to July 31, 2010. The relationship of DM to survival both as a categorical and time-dependent variable was studied. Fifty-three percent of patients had DM. Overall median survival was 5.2 (95% CI 3.8-6.6) years. At study end, 52% of patients had died, of whom 64% had DM. Estimated median survival was 10 years in patients without DM, 5.0 (3.3-6.8) years in patients with DM pre- and post-LTx and 4.3 (3.1-5.5) years in patients with new onset DM. As a time-dependent covariate, DM was the strongest risk factor for mortality, hazard ratio 3.96 (2.85-5.51). Bronchiolitis obliterans syndrome was the main cause of death in all patients surviving >90 days, but its incidence was not increased in patients with DM. Further studies are warranted to determine whether improved glycemic control could improve outcomes in LTx recipients.

摘要

肺移植(LTx)后的存活率仍然明显低于其他实体器官移植。糖尿病(DM)是一个未被充分研究的 LTx 受者死亡风险因素。值得注意的是,DM 发病时间与生存率的关系,以及 DM 相关超额死亡率的实际原因均未被描述。我们确定了在本机构于 2001 年 1 月 1 日至 2010 年 7 月 31 日期间接受 LTx 的 386 名连续成年患者的 DM 状态、DM 诊断日期和全因死亡率。研究了 DM 作为分类和时间依赖性变量与生存率的关系。53%的患者患有 DM。总体中位生存期为 5.2(95%CI 3.8-6.6)年。研究结束时,52%的患者死亡,其中 64%患有 DM。无 DM 的患者估计中位生存期为 10 年,LTx 前和 LTx 后患有 DM 的患者为 5.0(3.3-6.8)年,新诊断为 DM 的患者为 4.3(3.1-5.5)年。作为时间依赖性协变量,DM 是死亡率的最强危险因素,风险比为 3.96(2.85-5.51)。在所有存活超过 90 天的患者中,闭塞性细支气管炎综合征是死亡的主要原因,但 DM 患者的发病率并未增加。需要进一步研究以确定改善血糖控制是否可以改善 LTx 受者的结局。

相似文献

1
Diabetes is a major risk factor for mortality after lung transplantation.糖尿病是肺移植后死亡的一个主要危险因素。
Am J Transplant. 2014 Feb;14(2):438-45. doi: 10.1111/ajt.12561. Epub 2014 Jan 8.
2
The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.阿仑单抗和巴利昔单抗诱导治疗对双肺移植受者生存及闭塞性细支气管炎综合征发生时间的影响
Am J Transplant. 2016 Aug;16(8):2334-41. doi: 10.1111/ajt.13739. Epub 2016 May 23.
3
Gender differences in long-term survival post-transplant: A single-institution analysis in the lung allocation score era.移植后长期生存的性别差异:肺分配评分时代的单机构分析
Clin Transplant. 2017 Mar;31(3). doi: 10.1111/ctr.12889. Epub 2017 Feb 8.
4
Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center.肺移植中糖尿病的组织管理:单中心血糖控制与患者生存情况研究
Transplant Proc. 2019 Dec;51(10):3375-3384. doi: 10.1016/j.transproceed.2019.07.019. Epub 2019 Nov 14.
5
The Munich-LTX-Score: predictor for survival after lung transplantation.慕尼黑-LTX 评分:肺移植后生存的预测因子。
Clin Transplant. 2012 Jan-Feb;26(1):173-83. doi: 10.1111/j.1399-0012.2011.01573.x. Epub 2011 Dec 20.
6
Epidemiology and outcomes of deep surgical site infections following lung transplantation.肺移植术后深部手术部位感染的流行病学和结局。
Am J Transplant. 2013 Aug;13(8):2137-45. doi: 10.1111/ajt.12292. Epub 2013 May 24.
7
Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors.肺移植受者的移植后糖尿病:发病率及危险因素
Eur J Cardiothorac Surg. 2008 May;33(5):844-8. doi: 10.1016/j.ejcts.2008.01.050. Epub 2008 Mar 12.
8
Analysis of the waitlist performance and post-transplant outcomes of lung transplant in elderly recipients in Korea: A nationwide cohort study.韩国老年肺移植受者的候补名单表现和移植后结局分析:一项全国性队列研究。
Clin Transplant. 2024 Sep;38(9):e15299. doi: 10.1111/ctr.15299.
9
Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients.血糖控制不佳与肺移植受者生存率降低相关。
Transplantation. 2017 Sep;101(9):2200-2206. doi: 10.1097/TP.0000000000001555.
10
Chronic rejection following lung transplantation. Incidence, time pattern and consequences.肺移植后的慢性排斥反应。发生率、时间模式及后果。
Eur J Cardiothorac Surg. 1993;7(6):319-23; discussion 324. doi: 10.1016/1010-7940(93)90174-a.

引用本文的文献

1
Metformin alleviates lung ischemia‑reperfusion injury via the SIRT1 pathway following lung transplantation in diabetic rats.二甲双胍通过SIRT1通路减轻糖尿病大鼠肺移植后的肺缺血-再灌注损伤。
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13652. Epub 2025 Aug 14.
2
Effects of Elevated Glucose on Bacterial Respiratory Infections in Cystic Fibrosis and Chronic Airway Diseases.高血糖对囊性纤维化和慢性气道疾病中细菌呼吸道感染的影响。
Int J Mol Sci. 2025 Jun 11;26(12):5597. doi: 10.3390/ijms26125597.
3
One-Year Mortality After Lung Transplantation: Experience of a Single French Center Between 2012 and 2021.
肺移植后 1 年的死亡率:2012 年至 2021 年期间法国单一中心的经验。
Ann Transplant. 2024 Aug 20;29:e944420. doi: 10.12659/AOT.944420.
4
Metformin attenuates lung ischemia-reperfusion injury and necroptosis through AMPK pathway in type 2 diabetic recipient rats.二甲双胍通过 AMPK 通路减轻 2 型糖尿病受体大鼠肺缺血再灌注损伤和坏死性凋亡。
BMC Pulm Med. 2024 May 14;24(1):237. doi: 10.1186/s12890-024-03056-z.
5
Metabolic complications in lung transplantation for cystic fibrosis - A case control study.囊性纤维化肺移植中的代谢并发症——一项病例对照研究
Heliyon. 2024 Apr 24;10(9):e30034. doi: 10.1016/j.heliyon.2024.e30034. eCollection 2024 May 15.
6
Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016-2020.2016年至2020年期间西班牙特发性肺纤维化患者与非特发性肺纤维化患者肺移植的趋势与结果
Healthcare (Basel). 2023 May 24;11(11):1534. doi: 10.3390/healthcare11111534.
7
Development of the Lung Transplant Frailty Scale (LT-FS).肺移植衰弱量表(LT-FS)的制定。
J Heart Lung Transplant. 2023 Jul;42(7):892-904. doi: 10.1016/j.healun.2023.02.006. Epub 2023 Feb 20.
8
Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination.成人肺移植受者中依维莫司为基础的免疫抑制策略:钙调磷酸酶抑制剂最小化与钙调磷酸酶抑制剂消除。
Transpl Int. 2023 Jan 20;36:10704. doi: 10.3389/ti.2023.10704. eCollection 2023.
9
Recipient Management before Lung Transplantation.肺移植前的受者管理。
J Chest Surg. 2022 Aug 5;55(4):265-273. doi: 10.5090/jcs.22.042.
10
Survival difference between high-risk and low-risk CFTR genotypes after lung transplant.肺移植后高危和低危 CFTR 基因型之间的生存差异。
J Heart Lung Transplant. 2022 Oct;41(10):1511-1519. doi: 10.1016/j.healun.2022.04.009. Epub 2022 May 1.